134 related articles for article (PubMed ID: 23334230)
21. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene.
Chiari R; Foury F; De Plaen E; Baurain JF; Thonnard J; Coulie PG
Cancer Res; 1999 Nov; 59(22):5785-92. PubMed ID: 10582700
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with melanoma incidence and prognosis.
Lee JE
Semin Surg Oncol; 1996; 12(6):379-85. PubMed ID: 8914201
[TBL] [Abstract][Full Text] [Related]
23. Microphthalmia transcription factor: a specific marker for malignant melanoma.
Vachtenheim J; Borovanský J
Prague Med Rep; 2004; 105(3):318-24. PubMed ID: 15782558
[TBL] [Abstract][Full Text] [Related]
24. Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma.
Yang L; Chen Y; Cui T; Knösel T; Zhang Q; Geier C; Katenkamp D; Petersen I
Hum Pathol; 2012 Sep; 43(9):1463-70. PubMed ID: 22406360
[TBL] [Abstract][Full Text] [Related]
25. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
26. [Advances in cellular immunotherapy for malignant melanoma].
López M; Escobar A; Alfaro J; Fodor M; Larrondo M; Ferrada C; Salazar-Onfray F
Rev Med Chil; 2004 Sep; 132(9):1115-26. PubMed ID: 15543770
[TBL] [Abstract][Full Text] [Related]
27. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma.
Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP
Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497
[TBL] [Abstract][Full Text] [Related]
28. [Molecular and immunohistochemical diagnostics in melanoma].
Schilling B; Griewank KG
Hautarzt; 2016 Jul; 67(7):511-8. PubMed ID: 27270408
[TBL] [Abstract][Full Text] [Related]
29. Benign nodal nevi frequently harbor the activating V600E BRAF mutation.
Taube JM; Begum S; Shi C; Eshleman JR; Westra WH
Am J Surg Pathol; 2009 Apr; 33(4):568-71. PubMed ID: 19033861
[TBL] [Abstract][Full Text] [Related]
30. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
31. The immune system--a hidden treasure for biomarker discovery in cutaneous melanoma.
Neagu M
Adv Clin Chem; 2012; 58():89-140. PubMed ID: 22950344
[TBL] [Abstract][Full Text] [Related]
32. Update of diagnostic and prognostic markers in cutaneous malignant melanoma.
Reed JA; Albino AP
Clin Lab Med; 2000 Dec; 20(4):817-38. PubMed ID: 11221516
[TBL] [Abstract][Full Text] [Related]
33. Molecular cytogenetics of cutaneous melanocytic lesions - diagnostic, prognostic and therapeutic aspects.
Blokx WA; van Dijk MC; Ruiter DJ
Histopathology; 2010 Jan; 56(1):121-32. PubMed ID: 20055910
[TBL] [Abstract][Full Text] [Related]
34. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
35. Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion.
Takata M; Lin J; Takayanagi S; Suzuki T; Ansai S; Kimura T; Cerroni L; Saida T
Br J Dermatol; 2007 Jun; 156(6):1287-94. PubMed ID: 17535228
[TBL] [Abstract][Full Text] [Related]
36. Targeting oncogenic drivers and the immune system in melanoma.
McArthur GA; Ribas A
J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
[TBL] [Abstract][Full Text] [Related]
37. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
38. How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis.
Hatzimichael E; Syed N; Lo Nigro C; Rao B; Crook T
Expert Rev Mol Diagn; 2014 Jul; 14(6):639-42. PubMed ID: 24926921
[TBL] [Abstract][Full Text] [Related]
39. Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice.
Paschen A; Song M; Osen W; Nguyen XD; Mueller-Berghaus J; Fink D; Daniel N; Donzeau M; Nagel W; Kropshofer H; Schadendorf D
Clin Cancer Res; 2005 Jul; 11(14):5241-7. PubMed ID: 16033842
[TBL] [Abstract][Full Text] [Related]
40. Immunological detection of altered signaling molecules involved in melanoma development.
Kawakami Y; Sumimoto H; Fujita T; Matsuzaki Y
Cancer Metastasis Rev; 2005 Jun; 24(2):357-66. PubMed ID: 15986143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
